Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

janssen pharmaceutica n.v. - imazalil - emulsifiable concentrate - imazalil imidazole active 500.0 g/l - fungicide - citrus - post-harvest dip | potato - post-harvest | rockmelon or canteloup - post-harvest | canteloup | musk melon - alternaria rot | blue mould on citrus - p. italicum | fusarium fruit rot | fusarium spp. | gangrene - phoma exigua | green mould | penicillium spp. | silver scurf | fusarium patch

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - daratumumab -

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - daratumumab -

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ibrutinib -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - etravirine - tablet - 200mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - rad26.cov2-s -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

janssen pharmaceutica (pty) ltd - injection - see ingredients - each 0,5 ml dose contains ad26.cov2.s, recombinant 5 x 10(10) virus particles

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl).imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5.1).imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy.imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - etravirine - hiv infections - non-nucleoside reverse transcriptase inhibitors, antivirals for systemic use - intelence, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human-immunodeficiency-virus-type-1 (hiv-1) infection in antiretroviral-treatment-experienced adult patients and in antiretroviral-treatment-experienced paediatric patients from six years of age.this indication is based on week-48 analyses from two phase-iii trials in highly pretreated patients where intelence was investigated in combination with an optimised background regimen (obr) which included darunavir/ritonavir. the indication in paediatric patients is based on 48-week analyses of a single-arm, phase-ii trial in antiretroviral-treatment-experienced paediatric patients.